On November 10, 2026 Natera, Inc. (Nasdaq:NTRA), a global leader in cell-free DNA and precision medicine, reported that it has entered into a clinical collaboration agreement with Incyte (Nasdaq:INCY) for a new phase II study in colorectal cancer (CRC).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The trial will evaluate INCA33890, Incyte’s investigational bispecific immunotherapy, in patients with stage 2/3 CRC who have completed surgery and adjuvant chemotherapy (ACT), incorporating Signatera as both a primary and secondary endpoint. Following ACT, patients will undergo longitudinal testing with Signatera for up to 12 months, and those who test Signatera MRD-positive and have no evidence of radiographic disease may be eligible for enrollment and treatment in the study.
Natera’s clinical and real-world evidence, along with its expertise in MRD-guided clinical trial strategy and design, helped inform the study. Through the collaboration, Natera will also provide trial matching services to help identify patients for enrollment based on their Signatera MRD status and other eligibility criteria.
"We are excited by Incyte’s vision for this innovative trial, leveraging both our extensive real-world evidence and proven MRD capabilities," said Eric Matthews, General Manager, BioPharma, Natera. "Across a growing portfolio of TOMR studies, Signatera has been shown to enable early identification of patients at elevated risk of recurrence and supports enrollment into trials with treatment strategies that may alter the course of disease before radiographic progression occurs."
"Patients with colorectal cancer who remain MRD-positive after surgery and chemotherapy represent a population with substantial unmet need and a significantly elevated risk of recurrence," said Lois Erskine, Vice President and INCA 33890 Global Program Head, Incyte. "We look forward to the valuable insights this collaboration will enable as we work to advance this promising treatment and aim to improve outcomes for patients with CRC."
(Press release, Natera, NOV 10, 2026, View Source [SID1234674592])